Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Scientists have finally identified the stem cells behind tendons and ligaments — and found they may be driving one of the world's most common spine conditions. Researchers at Weill Cornell and Hospital for Special Surgery discovered that hyperactive versions of these cells contribute to lumbar spinal stenosis, affecting 103 million people globally. Excitingly, blood pressure drugs called calcium channel blockers may be repurposable as a treatment.
Scientists at Weill Cornell Medicine and Hospital for Special Surgery have cracked a long-standing mystery: identifying the master stem cells responsible for building and maintaining the body's tendons and ligaments. Published in Cell, the study confirms these cells can self-renew and generate the full spectrum of tendon and ligament cell types — a feat no previous candidate cell had definitively demonstrated.
The team then connected these stem cells to lumbar spinal stenosis, a condition affecting an estimated 103 million people worldwide, where enlarged spinal ligaments compress nerves and cause pain, numbness, and difficulty walking. Stem cells harvested from stenosis patients showed higher numbers and elevated calcium signaling compared to healthy controls — and when transplanted into mice, they triggered excessive tissue growth.
Crucially, blocking calcium signaling halted that overgrowth in a mouse model, pointing to calcium channel blockers — drugs already widely used for high blood pressure — as a potential repurposed therapy.
Key Takeaways:
Why it matters: This is the first research to identify a potential non-surgical therapeutic target for lumbar spinal stenosis, offering hope for the millions of patients currently left waiting until surgery becomes unavoidable.
